35 completed, 18 terminated, 13 recruiting, 11 unknown. 32 Phase 2, 26 Phase 1, 19 Not applicable, 3 Phase 4, 1 Phase 3.
Follow Hepatocellular Cancer: new trials by email Literature Review of Hepatocellular Cancer trials Research Report on Hepatocellular Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma TheraSphere® Yttrium-90 microspheres, Health Related Quality of Life Questionnaires (HRQOL) - Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma | Not applicable | Not yet recruiting | University of California, San Francisco | 64 | 2026-10-01 | 2026-10-06 |
| Patients With Hepatocellular Carcinoma (HCC) Fecal microbiota transplantation performed via colonoscopy., Simulated Colonoscopy With Placebo Capsules in Addition to Standard Treatment - Hepatocellular Carcinoma, Hepatocellular Cancer | Not applicable | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 52 | 2026-09-01 | 2026-07-21 |
| Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. PF-08634404, Ipilimumab - Carcinoma, Hepatocellular, Hepatocellular Cancer | Phase 1 / Phase 2 | Recruiting | Pfizer | 138 | 2025-12-01 | 2026-10-08 |
| A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine - Gastrointestinal Carcinoma, Pancreatic Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-09-09 | 2025-09-11 | |
| HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer HepQuant DuO, Multiparametric MRI Scans - Liver Cancer, Hepatocellular Carcinoma | Not applicable | Recruiting | Montefiore Medical Center | 40 | 2025-07-16 | 2026-08-11 |
| A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer SHR-1826, SHR-1826 and immunotherapy combination therapy - Hepatocellular Cancer | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 53 | 2025-05-01 | 2025-04-20 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) Lenvatinib, ABBV-324 - Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer | Phase 1 | Recruiting | AbbVie | 232 | 2025-04-14 | 2026-09-22 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors MDX2001 - Biliary Tract Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 330 | 2024-06-12 | 2026-10-15 |
| Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) Durvalumab, Gemcitabine, Nab paclitaxel - Pancreatic Cancer, Hepatocellular Cancer | Phase 2 | Recruiting | AHS Cancer Control Alberta | 62 | 2023-07-05 | 2025-06-26 |
| SIRT With Tremelimumab and Durvalumab for Resectable HCC Durvalumab, Tremelimumab, SIRT - Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma | Phase 1 | Active not recruiting | Jiping Wang, MD, PhD | 20 | 2023-04-21 | 2026-08-13 |
| Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria Atezolizumab, Bevacizumab - Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 4 | Enrolling by invitation | The Methodist Hospital Research Institute | 24 | 2023-01-30 | 2026-10-08 |
| Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors Q702, Pembrolizumab - Esophageal Cancer, Gastric Cancer | Phase 1 / Phase 2 | Active not recruiting | Qurient Co., Ltd. | 120 | 2023-01-12 | 2026-02-24 |
| Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab - Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 2 | Recruiting | Asan Medical Center | 138 | 2022-10-22 | 2025-02-21 |
| A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two - Hepatocellular Carcinoma, Solid Tumor | Phase 1 / Phase 2 | Terminated | Omega Therapeutics | 24 | 2022-08-19 | 2025-02-03 |
| Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib Anlotinib;Toripalimab - Hepatocellular Cancer | Phase 2 | Unknown | Shen Feng | 30 | 2022-07-08 | 2022-07-12 |
| Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm True circular microwave needle - Hepatocellular Cancer, Microwave Ablation | Not applicable | Unknown | Tianjin Third Central Hospital | 60 | 2022-06-22 | 2022-12-14 |
| A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors vobramitamab duocarmazine, lorigerlimab - Advanced Solid Tumor, Castration-Resistant Prostatic Cancer | Phase 1 | Completed | MacroGenics | 31 | 2022-04-19 | 2025-10-14 |
| A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors TAK-500, Pembrolizumab, Tocilizumab - Pancreatic Cancer, Hepatocellular Cancer | Phase 1 / Phase 2 | Terminated | Takeda | 61 | 2022-04-14 | 2026-01-22 |
| Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma Curative-intent liver resection - Carcinoma, Hepatocellular, Hepatocellular Cancer | Completed | Eastern Hepatobiliary Surgery Hospital | 3650 | 2022-01-01 | 2026-09-28 |
Showing 20 of 91. Sign in to see all of them.
Liver Neoplasms (91) · Carcinoma, Hepatocellular (28) · Pancreatic Neoplasms (17) · Colorectal Neoplasms (13) · Breast Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (10) · Stomach Neoplasms (10) · Cholangiocarcinoma (8) · Esophageal Neoplasms (8) · Colonic Neoplasms (7) · Melanoma (7) · Kidney Neoplasms (6) · Neoplasms (6) · Carcinoma, Renal Cell (5) · Fibrosis (5)
Digestive System Neoplasms (91) · Neoplasms by Site (91) · Digestive System Diseases (90) · Liver Diseases (87) · Neoplasms (85) · Neoplasms by Histologic Type (47) · Neoplasms, Glandular and Epithelial (44) · Carcinoma (40) · Adenocarcinoma (39) · Gastrointestinal Diseases (25) · Gastrointestinal Neoplasms (23) · Colonic Diseases (20) · Intestinal Diseases (20) · Intestinal Neoplasms (20) · Endocrine Gland Neoplasms (19)
Sorafenib (12) · Bevacizumab (4) · Nivolumab (4) · Cyclophosphamide (3) · durvalumab (3) · fludarabine (3) · tremelimumab (3) · Blood Specimen Collection (2) · Ipilimumab (2) · Oxaliplatin (2) · Radiofrequency Ablation (2) · aldesleukin (2) · atezolizumab (2) · pembrolizumab (2) · Albumin-Bound Paclitaxel (1)
National Cancer Institute (NCI) (8) · Massachusetts General Hospital (3) · Tianjin Third Central Hospital (3) · University of Missouri-Columbia (3) · Assistance Publique - Hôpitaux de Paris (2) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2) · Pfizer (2) · Takeda (2) · 7 Hills Pharma, LLC (1) · AHS Cancer Control Alberta (1) · AIO-Studien-gGmbH (1) · AbbVie (1) · Adaptimmune (1) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · Arbor Research Collaborative for Health (1)
United States (53) · China (12) · Germany (6) · Taiwan (6) · France (5) · Japan (5) · Canada (4) · South Korea (4) · Italy (3) · Singapore (3) · Spain (3) · United Kingdom (3) · Austria (2) · Hong Kong (2) · Israel (2)
Tim F Greten, M.D. (5) · Averell Sherker, MD (2) · Steven A Rosenberg, M.D. (2) · Xiang Jing, MD (2) · Abby Siegel, MD, MS (1) · Alexander Kirichenko, MD, PhD (1) · Amr Magdy Abdelfattah, consultant (1) · Andrea Bullock, MD, MPH (1) · Andrew Zhu, MD, PhD (1) · Apostolia Tsimberidou, MD, PhD (1) · Arkaduisz Z Dudek, MD (1) · Arndt Vogel, Prof. (1)
PMID 10400410, PMID 11413430, PMID 15273542, PMID 1598671, PMID 16810012, PMID 17005947, PMID 17538089, PMID 17943760, PMID 18054553, PMID 19011538, PMID 19638912, PMID 19770617, PMID 20130466, PMID 20199501, PMID 20554319, PMID 21688284, PMID 22012809, PMID 22335782, PMID 22821361, PMID 22994906, PMID 23239552, PMID 23495079, PMID 24677192, PMID 25065488, PMID 25195558, PMID 25488878, PMID 25779554, PMID 26258315, PMID 26461803, PMID 27152918, PMID 27326811, PMID 27339253, PMID 27517726, PMID 27567694, PMID 27647626, PMID 27756258, PMID 27865040, PMID 28514251, PMID 28796864, PMID 30832732, PMID 32557715, PMID 32776632, PMID 33016924, PMID 33681685, PMID 34097307, PMID 34155211, PMID 34297268, PMID 35279152, PMID 36082423, PMID 38030303
2017 (2), 2025 (2), 2016 (1), K23CA139005 (1), R01CA104524 (1), R01DK090129 (1), U01DK062444 (1), U01DK062467 (1), U01DK062483 (1), U01DK062494 (1), U01DK062498 (1), U01DK062531 (1), U01DK062536 (1), U01DK085515 (1), U01DK085563 (1)